Here are five things to know:
1. The two companies had a non-exclusive distribution agreement beginning in December 2012 for Aesculap to retain the rights to sell BoneScalpel disposables in the Untied States to certain, limited accounts.
2. The original distribution agreement covered binding supply agreements for varying periods of time, but none exceeded three years.
3. The new agreement brings the BoneScalpel back under Misonix’s control.
4. Misonix plans to continue growing their sales representative network in the Untied States for the BoneScalpel.
5. The BoneScalpel is an ultrasonic surgical system used for tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
“We are thankful to Aesculap and their professional management of, and efforts in, servicing these strategically important accounts,” said President and CEO of Misonix Michael A. McManus Jr. “The new agreement moves Misonix an important additional step further along the path of complete control of BoneScalpel distribution in the United States through the company’s own growing network of sales representatives.”
More articles on orthopedic devices:
8 key medtech industry trends in 2015
10 observations on spine tech innovation: Are we entering the Dark Ages?
ChoiceSpine acquires Baxano VEO Lateral Access & Interbody Fusion System: 5 key points
